Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Investigation of bone marrow microenvironment-induced drug resistance in acute lymphoblastic leukemia (ALL)

ABSTRACT: Investigation of bone marrow microenvironment-induced drug resistance in acute lymphoblastic leukemia (ALL)

PROVIDER: PRJNA822779 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR18588154.fastq.gz	Fastqsanger.gz
	SRR18588154_1.fastq.gz	Fastqsanger.gz
	SRR18588154_2.fastq.gz	Fastqsanger.gz
	SRR18588155_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 111

Similar Datasets

Transcriptional response in acute lymphoblastic leukaemia cells to bone marrow microenvironment

Project description:Glucocorticoids (GCs) and topoisomerase II inhibitors are used in the treatment of acute lymphoblastic leukaemia (ALL) due to their ability to induce cell death in lymphoid cells. GC-induced apoptosis is mediated by the glucocorticoid receptor (GR), whereas topoisomerase II inhibitors cause DNA damage and activate sensors of DNA damage including the tumour suppressor p53. In order to shed light on the role of the microenvironment in cell death and identify determinants of drug sensitivity we performed transcriptomic analysis in ALL cells treated with the synthetic glucocorticoid dexamethasone, and the topoisomerase II inhibitor etoposide combined with bone marrow-derived conditioned media (CM).

2017-08-30 | E-MTAB-4761 | biostudies-arrayexpress

The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution

Project description:The bone marrow microenvironment of leukemia plays a key role in leukemia progression, but its molecular complexity in pre-B acute lymphoblastic leukemia (B-ALL), the most common cancer in children, remains poorly understood. Here we use single-cell RNA sequencing to characterise the bone marrow microenvironment during B-ALL progression.

2020-07-27 | GSE148115 | GEO

Investigation of bone marrow microenvironment-induced drug resistance in acute lymphoblastic leukemia (ALL)

Project description:Bulk RNA-seq of B-ALL cells cocultured with bone marrow-mesenchymal stem cells (BM-MSC) identified that B-ALL acquire epithelial-mesenchymal transition (EMT) properties by interacting with primary bone marrow-mesenchymal stem cells (BM-MSC) and scRNA-seq dissected the hybrid cluster of adherent B-ALL (Adh B-ALL) harboring B-ALL and BM-MSC features induced by EMT program

2022-05-31 | GSE200039 | GEO

Bone marrow microenvironment mediated drug resistance in Acute promyelocytic leukemia

Project description:Bone marrow microenvironment mediated drug resistance in Acute promyelocytic leukemia

| PRJNA514741 | ENA

The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution

Project description:The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution

| PRJNA623280 | ENA

The Evolving Immune Microenvironment of B-cell Acute Lymphoblastic Leukemia [human bone marrow dataset]

Project description:The Evolving Immune Microenvironment of B-cell Acute Lymphoblastic Leukemia [human bone marrow dataset]

| PRJNA533995 | ENA

RNA-seq of primary human bone marrow derived mesenchymal stromal cells from pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients

Project description:To investigate the identity of the tumor microenvironment in acute lymphoblastic leukemia (B-ALL), the transcriptome of mesenchymal stromal cells derived from bone marrow of three pediatric patients at the onset of the disease was analyzed and compared with its normal counterpart.

2021-10-16 | E-MTAB-10838 | biostudies-arrayexpress

The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13

Project description:The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13

| PRJNA755248 | ENA

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment

Project description:The myeloma bone marrow microenvironment drives proliferation of malignant plasma cells and promotes resistance to therapy. Interleukin-6 (IL-6) and downstream JAK/STAT signaling are thought to be central components of these microenvironment-induced phenotypes. In a prior drug repurposing screen, we identified tofacitinib, a pan-JAK inhibitor FDA-approved for rheumatoid arthritis, as an agent that may reverse the tumor-stimulating effects of bone marrow mesenchymal stromal cells.Here, we validated both in vitro, in stromal-responsive human myeloma cell lines, and in vivo, in orthotopic disseminated murine xenograft models of myeloma, that tofacitinib showed both single-agent and combination therapeutic efficacy in myeloma models. Surprisingly, we found that ruxolitinib, an FDA-approved agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma effects. Combination with a novel irreversible JAK3-selective inhibitor also did not rescue ruxolitinib effects. RNA-seq and unbiased phosphoproteomics revealed that marrow stromal cells drive a JAK/STAT-mediated proliferative program in myeloma plasma cells, and tofacitinib reversed the large majority of these pro-growth signals. Taken together, our results suggest that tofacitinib specifically reverses the growth-promoting effects of the tumor microenvironment through blocking an IL-6-mediated signaling axis. As tofacitinib is already FDA-approved, these results can be rapidly translated into potential clinical benefits for myeloma patients.

2018-10-24 | PXD006581 | Pride

Alterations in miRNA abundance in acute lymphoblastic leukemia (ALL) cell lines influenced by the bone marrow microenvironment

Project description:For initial profiling to identify subsequent targets for more in depth investigation, total RNA was isolated from Sup-B15 ALL cells cultured in media only or in co-culture with bone marrow stromal cells (BMSC) or human osteoblasts (HOB) from triplicate independent cultures. RNA was processed by LC Sciences and miRNA microarray assays completed as previously described (Liu W., et al. Chin Med J (Engl) 2009).

2016-05-31 | E-MTAB-4744 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data